DMW - Deutsche Medizinische Wochenschrift, Table of Contents Dtsch Med Wochenschr 2013; 138(05): 180-182DOI: 10.1055/s-0032-1327410 Hämatologie und Onkologie | Commentary Onkologie © Georg Thieme Verlag KG Stuttgart · New York Mammakarzinom: Tumorbiologie-basierte Konzepte für operative und medikamentöse Therapie Breast cancer: Tumor biology-based concepts for surgical and drug treatment N. Harbeck 1 Brustzentrum der Universität München, Standorte: Frauenklinik Großhadern und Maistraße-Innenstadt › Author Affiliations Recommend Article Abstract Buy Article Schlüsselwörter SchlüsselwörterMammakarzinom - Sentinel-Lymphknoten - molekulare Subtypen - neoadjuvante Therapie - zielgerichtete Therapie Keywords Keywordsbreast cancer - sentinel lymph nodes - molecular subtypes - neoadjuvant therapy - targeted therapy Full Text References Literatur 1 Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-529 2 Baselga J, Cortés J, Kim SB et al. CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119 3 Bastien RR, Rodríguez-Lescure A, Ebbert MT et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics 2012; 5: 44 4 Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70 5 Dowsett M, Nielsen TO, A’Hern R et al. International Ki-67 in Breast Cancer Working Group. et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011; 103: 1656-64 6 Fisher B, Jeong JH, Anderson S et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002; 347: 567-75 7 Galimberti V, Chifu C, Rodriguez Perez S et al. Positive axillary sentinel lymph node: is axillary dissection always necessary?. Breast 2011; 20 (Suppl. 03) 96-8 8 Giuliano AE, Hunt KK, Ballman KV et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAMA 2011; 305: 569-575 9 Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747 10 Harbeck N, Rody A. Lost in translation? Estrogen receptor status and endocrine responsiveness in breast cancer. J Clin Oncol 2012; 30: 686-689 11 Kühn T. Sentinel lymph node biopsy in early breast cancer. Breast Care (Basel) 2011; 6: 185-191 12 Morrow M, Harris JR, Schnitt SJ. Surgical margins in lumpectomy for breast cancer – bigger is not better. N Engl J Med 2012; 367: 79-82 13 von Minckwitz G, Untch M, Blohmer JU et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796-1804 14 Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 2001; 98: 10869-74 15 Swain SM, Kim SB, Cortes J et al. Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC). Cancer Res 2012; 72 (Suppl. 24) P5-18-26 16 Verma S, Miles D, Gianni L et al. EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-1791
